Overview
In recent years, adoptive T-cell therapy (ACT) has emerged as a potent and viable type of therapeutic intervention, which is applicable to a variety of oncological and non-oncological indications. Owing to its obvious benefits, which include high target specificity, customization potential and the ability to generate immunological memory, this form of therapy has garnered significant attention among drug developers, investors and consumers, alike. In fact, several of the initial variants of T-cell based pharmacological interventions, namely those based on chimeric antigen receptors (CARs), and antigen sensitized T-cell receptors (TCRs), are already approved and available in the market. Lately, several novel types of T-cell therapies, such as γδ T-cells, Tregs, activated T-cells, virus-driven T-cells and T-cell vaccines, have demonstrated therapeutic proof-of-concept and shown promise in the early stages of clinical research, as well. Much like their predecessors, these experimental treatment paradigms are also capable of selectively eradicating diseased cells from the body and are characterized by favorable side effect profiles. At present, the novel T-cell immunotherapies pipeline features over 200 product candidates and is anticipated to grow in the foreseen future. Further, more than 35 such therapies, including Tab-cel® (Atara Biotherapeutics), CLBS03 (Caladrius Biosciences), TVI-Brain-1 (TVAX Biomedical), Viralym-M (AlloVir) and ALS001 (Coya Therapeutics), are already being evaluated in the advanced stages of development.
So far, more than 105 academic/research institutes, as well as over 50 industry players, across the world, have made notable contributions to this upcoming segment of the T-cell immunotherapies market. Moreover, multiple collaborations have been inked between both industry and non-industry players in order to advance the development of various pipeline candidates, over the past decade alone. It is also worth highlighting that, in the last five years, capital investments worth over USD 4 billion were made by VC firms/other strategic investors with interest in the healthcare domain. Driven by promising clinical trial data and lucrative funding, this niche, but emerging market, is poised to witness healthy growth over the next decade.
Scope of the Report
The “Novel T-Cell Immunotherapies Market: Focus on γδ T-Cells, Tregs, Activated T-Cells, Virus-driven T-Cells and T-Cell Vaccines - Distribution by Type of T-cell Therapy (Activated T-cell, T-cell Vaccine, Treg and Virus-driven T-cell), Target Indications (Brain Tumor, Pancreatic Cancer, Breast Cancer, Lung Cancer, Nasopharyngeal Cancer, Multiple Myeloma, Hepatocellular Carcinoma, Post-transplant Infection, Diabetes and Others), Key Players and Key Geographies (North America, Europe, Asia Pacific and Rest of the World), Industry Trends and Global Forecast, 2021-2030” report features an extensive study of the current market landscape and the associated future potential. The report highlights efforts of both industry players and academic organizations.
Amongst other elements, the report features the following:
- A detailed assessment of the current market landscape of novel T-cell immunotherapies, with respect to type of T-cell therapy (activated T-cells, virus driven T-cells, Tregs, γδ T-cells, T-cell vaccines and NK T-cells), phase of development (preclinical, phase I, phase I/II, phase II, phase III and marketed), therapeutic area (oncological disorders, infectious diseases, post-transplant infections, autoimmune disorders, metabolic disorders and neurological disorders), popular target indication (lung cancer, breast cancer, cytomegalovirus infection, glioblastoma, hepatocellular carcinoma, acute myeloid leukemia, ovarian cancer, type 1 diabetes mellitus, sarcoma, HIV infections and pancreatic cancer), source of T-cell (autologous and allogeneic), route of administration (intravenous, intratumoral, subcutaneous, inhalation and intramuscular), dose frequency (multiple dose, single dose and split dose), target patient segment (children, adults and seniors), type of therapy (monotherapy and combination therapy) and type of developer (industry and non-industry). In addition, the chapter includes details related to novel T-cell immunotherapies developers, along with information on their respective year of establishment, company size, location of headquarters and most active players (in terms of number of pipeline candidates).
- An in-depth analysis of completed, ongoing and planned clinical studies of various novel T-cell immunotherapies, based on various relevant parameters, such as trial registration year, trial phase, trial recruitment status, study design, type of sponsor/collaborator, leading industry players (in terms of number of registered trials conducted), enrolled patient population and key geographical regions.
- An analysis of the partnerships that have been established in this domain during the period 2015-2021 (till March), covering R&D agreements, product development agreements, product licensing agreements, acquisitions, service agreements, manufacturing agreements and other related agreements.
- An analysis of investments that have been made into companies which have proprietary novel T-cell based products/technologies, during period 2014 and 2021 (till March). The various type of funding instances reported in this domain include seed financing, venture capital financing, capital raised from IPOs and subsequent public offerings, grants and debt financing.
- Detailed profiles of clinical stage, novel T-cell therapies (phase I/II or above); each profile features an overview of the therapy, current development status, key clinical trial results, dosage regimen, details related to its manufacturing and recent developments.
- A case study on manufacturing of cell therapy products, highlighting the key challenges associated with the production of such therapies. In addition, it features a detailed list of contract service providers and in-house manufacturers involved in this market.
- Elaborate profiles of prominent players engaged in the development of novel T-cell immunotherapies. Each profile features a brief overview of the company, details related to its financials (if available), product portfolio, recent developments and manufacturing capability.
- A case study on regulatory T-cells, highlighting the mechanism of Tregs, key challenges associated with the production of such therapies and recent developments in the Tregs market.
One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for novel T-cell immunotherapies over the coming decade. The report also includes likely sales forecasts of novel T-cell immunotherapies that are in the mid to late stages of development. Additionally, it features market size projections for the overall novel T-cell immunotherapies market, wherein both the current and upcoming opportunity is segmented across [A] type of T-cell therapy (activated T-cell, T-cell vaccine, Treg and virus-driven T-cell), [B] target indication (brain tumour, pancreatic cancer, breast cancer, lung cancer, nasopharyngeal cancer, multiple myeloma, hepatocellular carcinoma, post-transplant infection, diabetes and others), [C] key players and [D] key geographies (North America, Europe, Asia Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain.
The report features detailed transcripts of interviews held with the following individuals:
- Peter Hoang (Chief Executive Officer, Marker Therapeutics)
- Patrick Dougherty (Senior Vice President, Strategy, Planning and Operations, WindMIL Therapeutics)
Key Questions Answered
- What are the prevalent R&D trends related to novel T-cell immunotherapies?
- What are the key therapeutic areas for which novel T-cell immunotherapies have been/are being developed?
- What are the key challenges faced by stakeholders engaged in this domain?
- Who are the leading industry and non-industry players in this market?
- Which players have made significant investments in this domain?
- What type of partnership models are commonly adopted by industry stakeholders?
- What are the factors that are likely to influence the evolution of this upcoming market?
- How is the current and future market opportunity likely to be distributed across key market segments?
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. T-Cell Immunotherapies
3.2.1. Types of Novel T-Cell Immunotherapies
3.2.1.1. Fucosylated T-Cell Therapies
3.2.1.2. Gamma Delta T-Cell Therapies
3.2.1.3. PD-1 Knockout Engineered T-Cell Therapies
3.2.1.4. TAC T-Cell Therapies
3.2.1.5. T-Cell Vaccines
3.2.1.6. Treg Cell Therapies
3.2.1.7. Virus-Driven T-Cell Therapies
3.3. Key Considerations for Developing T-Cell Immunotherapies
3.4. Concluding Remarks
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Novel T-Cell Immunotherapies: Overall Market Landscape
4.2.1. Analysis by Type of T-Cell Therapy
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Popular Target Indications
4.2.5. Analysis by Source of T-Cell
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Dose Frequency
4.2.8. Analysis by Target Patient Segment
4.2.9. Analysis by Type of Therapy
4.2.10. Analysis by Type of Developer
4.3. Novel T-cell Immunotherapies: List of Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis By Company Size
4.3.3. Analysis By Location of Headquarters
4.3.4. Key Industry Players: Analysis by Number of Pipeline Candidates
4.3.5. Key Non-Industry Players: Analysis by Number of Pipeline Candidates
5. NOVEL T-CELL IMMUNOTHERAPY PROFILES
5.1. Chapter Overview
5.2. Immuncell-LC (GC Pharma)
5.2.1. Therapy Overview
5.3. Cytovir CMV T-Cells (Kuur Therapeutics)
5.3.1. Therapy Overview
5.4. TT10: EB-VST (Tessa Therapeutics)
5.4.1. Therapy Overview
5.5. Tab-cel (tabelecleucel) (Atara Biotherapeutics)
5.5.1. Therapy Overview
5.6. Viralym-M (ALVR105) (AlloVir)
5.6.1. Therapy Overview
5.7. CLBS03 (Caladrius Biosciences)
5.7.1. Therapy Overview
5.8. TVI-Brain-1 (TVAX Biomedical)
5.8.1. Therapy Overview
5.9. ATA230 (Atara Biotherapeutics)
5.9.1. Therapy Overview
5.10. MILs (WindMIL Therapeutics)
5.10.1. Therapy Overview
5.11. Tcelna (Opexa Therapeutics)
5.11.1. Therapy Overview
6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Novel T-Cell Immunotherapies: Clinical Trial Analysis
6.3.1. Analysis by Trial Registration Year
6.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
6.3.3. Analysis by Trial Phase
6.3.4. Analysis by Trial Recruitment Status
6.3.5. Analysis by Study Design
6.3.6. Analysis by Type of Sponsor / Collaborator
6.3.7. Leading Industry Players: Analysis by Number of Registered Trials
6.3.8. Leading Non-Industry Players: Analysis by Number of Registered Trials
6.3.9. Analysis by Number of Registered Trials and Geography
6.3.10. Analysis by Enrolled Patient Population and Geography
6.3.11. Analysis by Trial Recruitment Status and Geography
7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Novel T-Cell Immunotherapies Market: Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Year and Type of Partnership
7.3.4. Analysis by Type of Partnership and Type of T-Cell Therapy
7.3.5. Analysis by Target Therapeutic Area
7.3.6. Most Active Players: Analysis by Number of Partnerships
7.3.7. Analysis by Geography
7.3.7.1. Region-wise Distribution
7.3.7.2. Country-wise Distribution
8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Type of Funding
8.3. Novel T-Cell Immunotherapies Market: Funding and Investment Analysis
8.3.1. Analysis by Year of Investment
8.3.2. Analysis by Amount Invested
8.3.3. Analysis by Type of Funding
8.3.4. Analysis by Type of T-Cell Therapy
8.3.5. Most Active Players: Analysis by Number of Funding Instances
8.3.6. Most Active Investors: Analysis by Number of Funding Instances
8.3.7. Analysis by Type of Investor
8.3.8. Analysis by Geography
9. CASE STUDY ON CELL THERAPY MANUFACTURING
9.1. Chapter Overview
9.2. Overview of Cell Therapy Manufacturing
9.3. Cell Therapy Manufacturing Models
9.3.1. Centralized Manufacturing Model
9.3.2. Decentralized Manufacturing Model
9.4. Scalability of Cell Therapy Manufacturing Processes
9.4.1. Scale-Up
9.4.2. Scale-Out
9.5. Types of Cell Therapy Manufacturers
9.6. Key Challenges associated with Manufacturing of Cell Therapies
9.7. Factors Affecting the Cell Therapy Manufacturing Process
9.7.1. Characterization
9.7.2. Cost of Goods
9.8. Automation of Cell Therapy Manufacturing Process
9.9. Cell Therapy Manufacturing Supply Chain
9.10. Companies with In-House Capabilities
9.11. Contract Manufacturers
9.12. Regulatory Landscape
10. COMPANY PROFILES
10.1. Chapter Overview
10.2. Atara Biotherapeutics
10.3. AlloVir
10.4. Eureka Therapeutics
10.5. Eutilex
10.6. GammaDelta Therapeutics
10.7. NexImmune
10.8. OSE Immunotherapeutics
10.9. Tevogen Bio
10.10. WindMIL Therapeutics
11. CASE STUDY ON RECENT DEVELOPMENTS IN TREG TARGETTING THERAPIES
11.1. Chapter Overview
11.2. Treg Targeting Therapies
11.2.1. Mechanism of Action of Tregs
11.3 Recent Developments Related to Treg Targeting Therapies
12. MARKET SIZING AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Scope and Limitations
12.3. Key Assumptions and Forecast Methodology
12.4. Global Novel T-Cell Immunotherapies Market
12.4.1. Novel T-Cell Immunotherapies Market: Distribution by Type of T-Cell Therapy
12.4.2. Novel T-Cell Immunotherapies Market: Distribution by Target Indications
12.4.3. Novel T-Cell Immunotherapies Market: Distribution by Key Players
12.4.4. Novel T-Cell Immunotherapies Market: Distribution by Geography
12.5. Novel T-Cell Immunotherapies Market: Value Creation Analysis
12.6. Novel T-Cell Immunotherapies Market: Product Wise Sales Forecast
12.6.1. Cytovir CMV T-Cells (Kuur Therapeutics)
12.6.1.1. Target Patient Population
12.6.1.2. Sales Forecast
12.6.1.3. Net Present Value
12.6.1.4. Value Creation Analysis
12.6.2. Immuncell-LC (GC Pharma)
12.6.2.1. Target Patient Population
12.6.2.2. Sales Forecast
12.6.2.3. Net Present Value
12.6.2.4. Value Creation Analysis
12.6.3. TT10: EB-VST (Tessa Therapeutics)
12.6.3.1. Target Patient Population
12.6.3.2. Sales Forecast
12.6.3.3. Net Present Value
12.6.3.4. Value Creation Analysis
12.6.4. TVI-Brain-1 (TVAX Biomedical)
12.6.4.1. Target Patient Population
12.6.4.2. Sales Forecast
12.6.4.3. Net Present Value
12.6.4.4. Value Creation Analysis
12.6.5. PD-1 Knockout Engineered T-Cells (Chengdu MedGenCell / Anhui Province Hospital)
12.6.5.1. Target Patient Population
12.6.5.2. Sales Forecast
12.6.5.3. Net Present Value
12.6.5.4. Value Creation Analysis
12.6.6. CLBS03 (Caladrius Biosciences)
12.6.6.1. Target Patient Population
12.6.6.2. Sales Forecast
12.6.6.3. Net Present Value
12.6.6.4. Value Creation Analysis
12.6.7. ATA230 (Atara Biotherapeutics)
12.6.7.1. Target Patient Population
12.6.7.2. Sales Forecast
12.6.7.3. Net Present Value
12.6.7.4. Value Creation Analysis
12.6.8. MILs (WindMIL Therapeutics / Bristol-Myers Squibb)
12.6.8.1. Target Patient Population
12.6.8.2. Sales Forecast
12.6.8.3. Net Present Value
12.6.8.4. Value Creation Analysis
12.6.9. Cytovir ADV T-Cells (Kuur Therapeutics)
12.6.9.1. Target Patient Population
12.6.9.2. Sales Forecast
12.6.9.3. Net Present Value
12.6.9.4. Value Creation Analysis
12.6.10. TAC01-CD19 (Triumvira Immunologics)
12.6.10.1. Target Patient Population
12.6.10.2. Sales Forecast
12.6.10.3. Net Present Value
12.6.10.4. Value Creation Analysis
12.6.11. PD-1 Knockout T Cells (Guangzhou Anjie Biomedical Technology)
12.6.11.1. Target Patient Population
12.6.11.2. Sales Forecast
12.6.11.3. Net Present Value
12.6.11.4. Value Creation Analysis
12.6.12. NEXI-0002 (NexImmune)
12.6.12.1. Target Patient Population
12.6.12.2. Sales Forecast
12.6.12.3. Net Present Value
12.6.12.4. Value Creation Analysis
12.6.13. ET140203 (Eureka Therapeutics)
12.6.13.1. Target Patient Population
12.6.13.2. Sales Forecast
12.6.13.3. Net Present Value
12.6.13.4. Value Creation Analysis
13. CONCLUDING REMARKS
14. EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2. Marker Biotherapeutics
14.2.1. Interview Transcript: Peter Hoang, Chief Executive Officer
14.3. WindMIL Therapeutics
14.3.1. Interview Transcript: Patrick Dougherty, Senior Vice President, Strategy, Planning and Operations
15. APPENDIX 1: TABULATED DATA
16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
List Of Figures
Figure 4.1 Novel T-Cell Immunotherapies: Distribution by Type of T-Cell Therapy
Figure 4.2 Novel T-Cell Immunotherapies: Distribution by Phase of Development`
Figure 4.3 Novel T-Cell Immunotherapies: Distribution by Therapeutic Area
Figure 4.4 Novel T-Cell Immunotherapies: Distribution by Popular Target Indications
Figure 4.5 Novel T-Cell Immunotherapies: Distribution by Source of T-Cell
Figure 4.6 Novel T-Cell Immunotherapies: Distribution by Route of Administration
Figure 4.7 Novel T-Cell Immunotherapies: Distribution by Dose Frequency
Figure 4.8 Novel T-Cell Immunotherapies: Distribution by Target Patient Segment
Figure 4.9 Novel T-Cell Immunotherapies: Distribution by Type of Therapy
Figure 4.10 Novel T-Cell Immunotherapies: Distribution by Type of Developer
Figure 4.11 Novel T-cell Immunotherapies Developers: Distribution by Year of Establishment
Figure 4.12 Novel T-cell Immunotherapies Developers: Distribution by Company Size
Figure 4.13 Novel T-cell Immunotherapies Developers: Distribution by Location of Headquarters
Figure 4.14 Key Industry Players: Distribution by Number of Pipeline Candidates
Figure 4.15 Key Non-Industry Players: Distribution by Number of Pipeline Candidates
Figure 6.1 Clinical Trial Analysis: Scope and Methodology
Figure 6.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2010 - 2021
Figure 6.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Figure 6.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 6.5 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 6.6 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year and TrialRecruitment Status
Figure 6.7 Clinical Trial Analysis: Distribution by Study Design
Figure 6.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 6.9 Leading Industry Players: Distribution by Number of Registered Trials
Figure 6.10 Leading Non-Industry Players: Distribution by Number of Registered Trials
Figure 6.11 Clinical Trial Analysis: Distribution of Number of Registered Trials by Geography
Figure 6.12 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Figure 6.13 Clinical Trial Analysis: Distribution of Trial Recruitment Status by Geography
Figure 7.1 Partnerships and Collaborations: Cumulative Distribution by Year, 2015-2021
Figure 7.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 7.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 7.4 Partnerships and Collaborations: Distribution by Type of Partnership and Type of T-Cell Therapy
Figure 7.5 Partnerships and Collaborations: Distribution by Target Therapeutic Area
Figure 7.6 Most Active Players: Distribution by Number of Partnerships
Figure 7.7 Partnerships and Collaborations: Distribution by Region (Continent-wise)
Figure 7.8 Partnerships and Collaborations: Distribution by Region (Country-wise)
Figure 8.1 Funding and Investment Analysis: Cumulative Distribution of Funding Instances by Year, 2014-2021
Figure 8.2 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, 2014-2021 (USD Million)
Figure 8.3 Funding and Investment Analysis: Distribution by Type of Funding
Figure 8.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 8.5 Funding and Investments Analysis: Distribution of Amount Invested by Type of T-Cell Therapy (USD Million)
Figure 8.6 Most Active Players: Distribution by Number of Funding Instances
Figure 8.7 Most Active Investors: Distribution by Number of Funding Instances
Figure 8.8 Funding and Investment Analysis: Distribution by Type of Investor
Figure 8.9 Funding and Investment Analysis: Distribution by Region (Continent-wise)
Figure 8.10 Funding and Investment Analysis: Distribution by Region (Country-wise)
Figure 9.1 Steps Involved in Cell Therapy Manufacturing Process
Figure 9.2 Centralized Manufacturing: Process Model
Figure 9.3 Decentralized Manufacturing: Process Model
Figure 9.4 Cell Therapy Manufacturing: Types of Manufacturers
Figure 9.5 Cell Therapy Manufacturing: Challenges and Drivers
Figure 9.6 Cell Therapies: Potency as a Critical Quality Attribute
Figure 9.7 Cell Therapy Manufacturing: Supply Chain Model
Figure 9.8 Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 11.1 Tregs-Cell Therapies: Mechanism of Action
Figure 12.1 Global Novel T-Cell Immunotherapies Market, 2021-2030 (USD Billion)
Figure 12.2 Novel T-Cell Immunotherapies Market: Distribution by Type of T-Cell Therapy
Figure 12.3 Novel T-Cell Immunotherapies Market: Distribution by Target Indication
Figure 12.4 Novel T-Cell Immunotherapies Market: Distribution by Key Players
Figure 12.5 Novel T-Cell Immunotherapies Market: Distribution by Geography
Figure 12.6 Cytovir CMV T-Cells (Kuur Therapeutics): Sales Forecast, till 2030 (USD Million)
Figure 12.7 Immuncell-LC (GC Pharma): Sales Forecast, till 2030 (USD Million)
Figure 12.8 TT10: EB-VST (Tessa Therapeutics): Sales Forecast, till 2030 (USD Million)
Figure 12.9 TVI-Brain-1 (TVAX Biomedical): Sales Forecast, till 2030 (USD Million)
Figure 12.10 PD-1 Knockout Engineered T-Cells (Chengdu MedGenCell / Anhui Province Hospital): Sales Forecast, till 2030 (USD Million)
Figure 12.11 CLBS03 (Caladrius Biosciences): Sales Forecast, till 2030 (USD Million)
Figure 12.12 ATA230 (Atara Biotherapeutics): Sales Forecast, till 2030 (USD Million)
Figure 12.13 MILs (WindMIL Therapeutics / Bristol-Myers Squibb): Sales Forecast, till 2030 (USD Million)
Figure 12.14 Cytovir ADV T-Cells (Kuur Therapeutics): Sales Forecast, till 2030 (USD Million)
Figure 12.15 TAC01-CD19 (Triumvira Immunologics): Sales Forecast, till 2030 (USD Million)
Figure 12.16 PD-1 Knockout T Cells (Guangzhou Anjie Biomedical Technology): Sales Forecast, till 2030 (USD Million)
Figure 12.17 NEXI-0002 (NexImmune): Sales Forecast, till 2030 (USD Million)
Figure 12.18 ET140203 (Eureka Therapeutics): Sales Forecast, till 2030 (USD Million)
Figure 13.1 Concluding Remarks: Overall Market Landscape
Figure 13.2 Concluding Remarks: Clinical Trial Analysis
Figure 13.3 Concluding Remarks: Partnerships and Collaborations
Figure 13.4 Concluding Remarks: Funding and Investment Analysis
Figure 13.5 Concluding Remarks: Market Forecast
List Of Tables
Table 4.1 Novel T-Cell Immunotherapies: Candidate Pipeline
Table 4.2 Novel T-Cell Immunotherapies: Information on Source of T-Cells, Route of Administration, Dose Frequency, Target Patient Segment and Type of Therapy
Table 4.3 Novel T-Cell Immunotherapies: List of Developers
Table 5.1 Novel T-Cell Immunotherapies: List of Therapies Profiled
Table 5.2 Therapy Profile: Immunecell-LC (GC Pharma)
Table 5.3 Therapy Profile: Cytovir CMV T-Cells (Kuur Therapeutics)
Table 5.4 Therapy Profile: TT10: EB-VST (Tessa Therapeutics)
Table 5.5 Therapy Profile: Tab-cel (tabelecleucel) (Atara Biotherapeutics)
Table 5.6 Therapy Profile: Viralym-M (ALVR105) (AlloVir)
Table 5.7 Therapy Profile: CLBS03 (Caladrius Biosciences)
Table 5.8 Therapy Profile: TVI-Brain-1 (TVAX Biomedical)
Table 5.9 Therapy Profile: ATA230 (Atara Biotherapeutics)
Table 5.10 Therapy Profile: MILs (WindMIL Therapeutics)
Table 5.11 Therapy Profile: Tcelna (Opexa Therapeutics)
Table 7.1 Novel T-Cell Immunotherapies Market: List of Partnerships and Collaborations, 2015-2021
Table 8.1 Novel T-Cell Immunotherapies: Funding and Investments, 2014-2021
Table 8.2 Novel T-Cell Immunotherapies: Summary of Investments
Table 10.1 Novel T-Cell Immunotherapy Developers: List of Companies Profiled
Table 10.2 Atara Biotherapeutics: Company Profile
Table 10.3 AlloVir: Company Profile
Table 10.4 Eureka Therapeutics: Company Profile
Table 10.5 Eutilex: Company Profile
Table 10.6 GammaDelta Therapeutics: Company Profile
Table 10.7 NexImmune: Company Profile
Table 10.8 OSE Immunotherapeutics: Company Profile
Table 10.9 Tevogen Bio: Company Profile
Table 10.10 WindMIL Therapeutics: Company Profile
Table 11.1 Treg Targeting Therapies: Candidate Pipeline
Table 11.2 Treg Targeting Therapies: Recent Developments
Table 12.1 Market Forecast of Novel T-Cell Immunotherapies: List of Molecules
Table 12.2 Cytovir CMV T-Cells (Kuur Therapeutics): Net Present Value (USD Million)
Table 12.3 Cytovir CMV T-Cells (Kuur Therapeutics): Value Creation Analysis (USD Million)
Table 12.4 Immuncell-LC (GC Pharma): Net Present Value (USD Million)
Table 12.5 Immuncell-LC (GC Pharma): Value Creation Analysis (USD Million)
Table 12.6 TT10: EB-VST (Tessa Therapeutics): Net Present Value (USD Million)
Table 12.7 TT10: EB-VST (Tessa Therapeutics): Value Creation Analysis (USD Million)
Table 12.8 TVI-Brain-1 (TVAX Biomedical): Net Present Value (USD Million)
Table 12.9 TVI-Brain-1 (TVAX Biomedical): Value Creation Analysis (USD Million)
Table 12.10 PD-1 Knockout Engineered T-Cells (Chengdu MedGenCell / Anhui Province Hospital): Net Present Value (USD Million)
Table 12.11 PD-1 Knockout Engineered T-Cells (Chengdu MedGenCell / Anhui Province Hospital): Value Creation Analysis (USD Million)
Table 12.12 CLBS03 (Caladrius Biosciences): Net Present Value (USD Million)
Table 12.13 CLBS03 (Caladrius Biosciences): Value Creation Analysis (USD Million)
Table 12.14 ATA230 (Atara Biotherapeutics): Net Present Value (USD Million)
Table 12.15 ATA230 (Atara Biotherapeutics): Value Creation Analysis (USD Million)
Table 12.16 MILs (WindMIL Therapeutics / Bristol-Myers Squibb): Net Present Value (USD Million)
Table 12.17 MILs (WindMIL Therapeutics / Bristol-Myers Squibb): Value Creation Analysis (USD Million)
Table 12.18 Cytovir ADV T-Cells (Kuur Therapeutics): Net Present Value (USD Million)
Table 12.19 Cytovir ADV T-Cells (Kuur Therapeutics): Value Creation Analysis (USD Million)
Table 12.20 TAC01-CD19 (Triumvira Immunologics): Net Present Value (USD Million)
Table 12.21 TAC01-CD19 (Triumvira Immunologics): Value Creation Analysis (USD Million)
Table 12.22 PD-1 Knockout T Cells (Guangzhou Anjie Biomedical Technology): Net Present Value (USD Million)
Table 12.23 PD-1 Knockout T Cells (Guangzhou Anjie Biomedical Technology): Value Creation Analysis (USD Million)
Table 12.24 NEXI-0002 (NexImmune): Net Present Value (USD Million)
Table 12.25 NEXI-0002 (NexImmune): Value Creation Analysis (USD Million)
Table 12.26 ET140203 (Eureka Therapeutics): Net Present Value (USDMillion)
Table 12.27 ET140203 (Eureka Therapeutics): Value Creation Analysis(USD Million)
Table 14.1 Marker Biotherapeutics: Company Snapshot
Table 14.2 WindMIL Therapeutics: Company Snapshot
Table 15.1 Novel T-Cell Immunotherapies: Distribution by Type of T-cell Therapy
Table 15.2 Novel T-Cell Immunotherapies: Distribution by Phase of Development`
Table 15.3 Novel T-Cell Immunotherapies: Distribution by Therapeutic Area
Table 15.4 Novel T-Cell Immunotherapies: Distribution by Popular Target Indications
Table 15.5 Novel T-Cell Immunotherapies: Distribution by Source of T-Cell
Table 15.6 Novel T-Cell Immunotherapies: Distribution by Route of Administration
Table 15.7 Novel T-Cell Immunotherapies: Distribution by Dose Frequency
Table 15.8 Novel T-Cell Immunotherapies: Distribution by Target Patient Segment
Table 15.9 Novel T-Cell Immunotherapies: Distribution by Type of Therapy
Table 15.10 Novel T-Cell Immunotherapies: Distribution by Type of Developer
Table 15.11 Novel T-cell Immunotherapies Developers: Distribution by Year of Establishment
Table 15.12 Novel T-cell Immunotherapies Developers: Distribution by Company Size
Table 15.13 Novel T-cell Immunotherapies Developers: Distribution by Location of Headquarters
Table 15.14 Key Industry Players: Distribution by Number of Pipeline Candidates
Table 15.15 Key Non-Industry Players: Distribution by Number of Pipeline Candidates
Table 15.16 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2010 - 2021
Table 15.17 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Table 15.18 Clinical Trial Analysis: Distribution by Trial Phase
Table 15.19 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 15.20 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year and TrialRecruitment Status
Table 15.21 Clinical Trial Analysis: Distribution by Study Design
Table 15.22 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 15.23 Leading Industry Players: Distribution by Number of Registered Trials
Table 15.24 Clinical Trial Analysis: Distribution of Number of Registered Trials by Geography
Table 15.25 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Table 15.26 Clinical Trial Analysis: Distribution of Trial Recruitment Status by Geography
Table 15.27 Partnerships and Collaborations: Cumulative Distribution by Year, 2015-2021
Table 15.28 Partnerships and Collaborations: Distribution by Type of Partnership
Table 15.29 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 15.30 Partnerships and Collaborations: Distribution by Type of Partnership and Type of T-Cell Therapy
Table 15.31 Partnerships and Collaborations: Distribution by Target Therapeutic Area
Table 15.32 Most Active Players: Distribution by Number of Partnerships
Table 15.33 Partnerships and Collaborations: Distribution by Region (Continent-wise)
Table 15.34 Partnerships and Collaborations: Distribution by Region (Country-wise)
Table 15.35 Funding and Investment Analysis: Cumulative Distribution of Funding Instances by Year, 2014-2021
Table 15.36 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, 2014-2020 (USD Million)
Table 15.37 Funding and Investment Analysis: Distribution by Type of Funding
Table 15.38 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Table 15.39 Funding and Investments Analysis: Distribution by Amount Invested by Type of T-Cell Therapies (USD Million)
Table 15.40 Most Active Players: Distribution by Number of Funding Instances
Table 15.41 Most Active Investors: Distribution by Number of Funding Instances
Table 15.42 Funding and Investment Analysis: Distribution by Type of Investor
Table 15.43 Funding and Investment Analysis: Distribution by Region (Continent-wise)
Table 15.44 Funding and Investment Analysis: Distribution by Region (Country-wise)
Table 15.45 Global Novel T-Cell Immunotherapies Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Billion)
Table 15.46 Novel T-Cell Immunotherapy Market: Distribution by Type of T-Cell Therapy
Table 15.47 Novel T-Cell Immunotherapy Market: Distribution by Target Indications
Table 15.48 Novel T-Cell Immunotherapy Market: Distribution by Key Players
Table 15.49 Novel T-Cell Immunotherapy Market: Distribution by Geography
Table 15.50 Cytovir CMV T-Cells (Kuur Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030: (USD Million)
Table 15.51 Immuncell-LC (GC Pharma): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 15.52 TT10: EB-VST (Tessa Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 15.53 TVI-Brain-1 (TVAX Biomedical): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 15.54 PD-1 Knockout Engineered T-Cells (Chengdu MedGenCell / Anhui Province Hospital): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 15.55 CLBS03 (Caladrius Biosciences): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 15.56 ATA230 (Atara Biotherapeutics): Sales Forecast, Conservative, Base and OptimisticScenarios, till 2030 (USD Million)
Table 15.57 MILs (WindMIL Therapeutics / Bristol-Myers Squibb): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 15.58 Cytovir ADV T-Cells (Kuur Therapeutics): Sales Forecast, Conservative, Base andOptimistic Scenarios, till 2030 (USD Million)
Table 15.59 TAC01-CD19 (Triumvira Immunologics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 15.60 PD-1 Knockout T Cells (Guangzhou Anjie Biomedical Technology): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 15.61 NEXI-0002 (NexImmune): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 15.62 ET140203 (Eureka Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 8VC
- Abingworth
- Acer Therapeutics
- Acorn Pacific Ventures
- Adaptate Biotherapeutics
- Agency for Science, Technology and Research (A*STAR)
- AgenTus Therapeutics
- Agenus
- Alexandria Venture Investments
- Allele Capital Partners
- AlloVir
- Andalusian Public Foundation for Health Research Management of Seville (FISEVI)
- Anhui Kedgene Biotechnology
- Anhui Provincial Hospital
- ARCH Venture Partners
- ArrowMark Partners
- ARSEP Foundation
- Assistance Publique – Hôpitaux de Paris (AP-HP)
- Atara Biotherapeutics
- Austin Health
- Autoimmunity Centers of Excellence
- Barer & Son Capital
- Bayer
- Baylor College of Medicine
- BB Pureos Bioventures
- Beijing 302 Hospital
- Beijing Cancer Hospital
- Beijing Doing Biomedical Technology
- Beijing GD Initiative Cell Therapy Technology
- Beijing Genomics Institute
- Beijing Mabworks Biotech
- Beijing Tongren Hospital
- Beijing Youan Hospital
- Bellicum Pharmaceuticals
- Benaroya Research Institute at Virginia Mason (BRI)
- Besançon University Hospital
- Beth Israel Deaconess Medical Center
- Betta Pharmaceuticals
- BHT Lifescience Australia
- Bill and Melinda Gates Foundation
- BioCentriq
- Bios Partners
- Biox Biosciences
- Blood and Tissue Bank
- Bloom Burton
- bluebird bio
- Bpifrance
- Brigham and Women's Hospital
- Bristol Myers Squibb
- British Society for Haematology
- Bordeaux University Hospital Center (CHU)
- Boston Children's Hospital
- Cairo University
- Caladrius Biosciences
- California Institute for Regenerative Medicine (CIRM)
- Cambridge University Hospitals NHS Foundation Trust
- Cancer Prevention Research Institute of Texas
- Cancer Research Institute
- Cancer Research Technology
- Case Western Reserve University
- Celldex Therapeutics
- Cell Medica
- Celgene
- Cellenkos
- Center for Cell and Gene Therapy
- Center for Clinical and Translational Sciences (CCTS)
- Centre for Commercialisation of Cancer Immunotherapy (C3i)
- Central Hospital, Nancy, France
- Central South University
- Charite – Universitatsmedizin Berlin
- Changi General Hospital (CGH)
- Chengdu MedGenCell
- Children's Hospital Los Angeles
- Children's Hospital of Philadelphia
- Children's National Research Institute (CNRI)
- Children's Oncology Group
- Children's Research Institute
- Chinese Academy of Medical Sciences
- Chinese PLA General Hospital (CPGH)
- Cincinnati Children's Hospital Medical Center
- City of Hope
- Clinical Research Malaysia (CRM)
- Cognate BioServices
- Columbia University
- Coya Therapeutics
- CRISPR Therapeutics
- Cryoport
- CytoMed Therapeutics
- Dana-Farber Cancer Institute
- DCVC Management
- Department of Health Valencia La Fe
- Diabetes Research Institute Foundation Canada (DRIFCan)
- DS Asset Management
- Duke-NUS Medical School
- Duke University
- Dutch Cancer Society
- EcoR1 Capital
- EDBI
- Emerson Collective
- Emmes
- Erciyes University
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Euchloe Bio (acquired by Tessa Therapeutics)
- Eureka Therapeutics
- European Commission
- Eutilex
- F2 Ventures
- Faculty of Medicine, University of Indonesia (FKUI)
- Fate Therapeutics
- Ferring Pharmaceuticals
- Fidelity Management and Research
- Fondazione IRCCS Policlinico San Matteo
- Fred Hutchinson Cancer Research Center
- Friedrich-Alexander University Erlangan-Nuremberg (FAU)
- French Blood Establishment (EFS)
- Friedreich’s Ataxia Research Alliance (FARA)
- Fuda Cancer Hospital
- GammaCell Bio-Technologies
- GammaDelta Therapeutics
- GC Pharma
- GentiBio
- Ghent University Hospital
- Gilde Healthcare
- Gilead Sciences
- GlaxoSmithKline
- G.N. Tech Venture
- GP Capital
- Guangdong Xiangxue Precision Medical Technology
- Guangzhou Anjie Biomedical Technology
- Guy's and St Thomas' NHS Foundation Trust
- Hackensack Meridian Health
- Hangzhou Cancer Hospital
- Hannover Medical School
- Harbin Medical University
- Harris Health System (formerly known as the Harris County Hospital District)
- Heidelberg University Hospital
- Heliconia Capital Management
- HengRui YuanZheng Bio-Technology
- Heritas Capital
- H. Lee Moffitt Cancer Center and Research Institute
- HMP Partners
- Hoxworth Blood Center
- Hunan Zhaotai Yongren Medical Innovation
- Icahn School of Medicine at Mount Sinai
- ILTOO Pharma
- Immune Tolerance Network
- Immunocore
- Imperial College London
- InnoCare Pharma
- International Multidisciplinary Research Foundation (IMRF)
- IN8bio
- Incyte
- Innovate UK
- Inserm
- Institute of Hematology and Blood Diseases Hospital
- Instituto de Investigación Sanitaria Valdecilla (IDIVAL)
- Intrexon
- IRCCS Company Hospital- University of Bologna
- ITOCHU
- Janssen Biotech
- JDRF T1D Fund
- Jinan University
- Johns Hopkins University
- Jonsson Comprehensive Cancer Center
- Juvenile Diabetes Research Foundation (JDRF)
- Kaiser Permanente
- Karst Peak Capital
- King’s College London
- KK Women's and Children's Hospital
- Knight Therapeutics
- Kolon Investment
- Kuur Therapeutics
- Kyverna Therapeutics
- LAVA Therapeutics
- Leukemia and Lymphoma Society
- Liana's Dream Foundation
- Lifeforce Capital
- Lightspeed Venture Partners
- Lilly Asia Ventures
- Lonza
- Ludwig Institute for Cancer Research
- Lupus Ventures
- Lyell Immunopharma
- Lymphact (acquired by GammaDelta Therapeutics)
- Mahidol University
- Maisonneuve-Rosemont Hospital
- Massachusetts General Hospital
- Matrix Capital Management
- Mayo Clinic
- MD Anderson Cancer Center
- Medical College of Wisconsin
- Medical Research Council
- Medical University of Lublin
- Medical University of Vienna
- Memorial Sloan Kettering Cancer Center
- Merck Sharp & Dohme
- Methodist Hospitals
- MIGAL Galilee Research Institute
- Miltenyi Biomedicine
- Miltenyi Biotec
- Ministry of Science and Higher Education, Poland
- MMH Institute for Transfusion Medicine
- Mogrify
- Mount Sinai Hospital
- MPM Capital
- MRL Ventures Fund
- Mubadala Investment Company
- Multiple Myeloma Research Foundation (MMRF)
- Nanjing Drum Tower Hospital (Nanjing Gulou Yi Yuan)
- Nanjing Medical University
- Nantes University Hospital
- National Cancer Institute
- National Center for Tumor Diseases (NCT)
- National Health and Medical Research Council (NHMRC)
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute for Health Research (NIHR)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institutes of Health (NIH)
- National Marrow Donor Program
- National University Hospital (NUH)
- Nationwide Children's Hospital
- ND Capital
- Nice University Hospital
- Neon Therapeutics
- New Enterprise Associates
- New York Medical College
- NexImmune
- Northpond Ventures
- Northwestern University
- Nova Immunotherapeutics
- Novartis Venture Fund
- Novo Ventures
- NYU Langone Health
- Oceanpine Capital
- Octagon Capital
- Ohio University
- Oncovir
- Opexa Therapeutics
- OrbiMed
- Orca Bio
- Ospedale San Raffaele
- OU Health Stephenson Cancer Center
- PapiVax Biotech
- Pancreatic Cancer Action Network
- University Paris-Est Creteil Val de Marne (formerly known as the Université Paris XII)
- Parker Institute for Cancer Immunotherapy
- Peking University People's Hospital
- Penn State Health Milton S. Hershey Medical Center
- Peter MacCallum Cancer Institute
- PersonGen BioTherapeutics (Suzhou)
- Pfizer
- Piedmont Capital Partners
- Pierce Phillips Charity
- Pierre and Marie Curie University (UPMC)
- Prometheus Laboratories
- Providence Cancer Institute
- Qiming Venture Partners
- QIMR Berghofer Medical Research Institute
- Quell Therapeutics
- Queensland Institute of Medical Research (QIMR) Berghofer
- RA Capital Management
- Radboud University
- Redmile Group
- Rho Federal Systems Division
- Roswell Park Cancer Institute
- Samsara BioCapital
- Sanford Health
- Sangamo Therapeutics
- Sanofi Ventures
- Seattle Children’s Research Institute
- Second Xiangya Hospital of Central South University
- Sengkang General Hospital
- Seoul National University Hospital (SNUH)
- Shanghai General Hospital
- Shanghai Houchao Biotechnology
- Shanghai iCELL Biotechnology
- Shanghai Jiao Tong University School of Medicine
- Shanghai Public Health Clinical Center
- Sheffield Institute for Translational Neuroscience
- Shenzhen Geno-Immune Medical Institute
- Shenzhen Hornetcorn Biotechnology
- Shenzhen Second People's Hospital
- Shenzhen Third People's Hospital
- Sichuan University
- Singapore General Hospital
- Siriraj Hospital
- Sixth Affiliated Hospital
- SNU Bio Angel
- SoftBank Vision Fund
- Solving Kids' Cancer
- Sonoma Biotherapeutics
- Specialized Medical Services-oncology
- SR One
- St. George's Hospital
- St. Jude Children’s Research Hospital
- Stanford University
- Sun Yat-sen University
- Surveyor Capital
- Syncona
- SYZ Cell Therapy
- Takeda Pharmaceutical
- Targazyme
- Temasek
- Tessa Therapeutics
- Tevogen Bio
- The Atlantic Philanthropies
- The Egyptian IVF-ET Center
- The First Affiliated Hospital of Xi'an Jiaotong University
- The First Affiliated Hospital of Guangdong Pharmaceutical University
- The First Affiliated Hospital of Guangzhou Medical University
- The First Affiliated Hospital of Soochow University
- The Francis Crick Institute
- The First People's Hospital of Lianyungang
- The Invus Group
- The University of Alabama at Birmingham
- The University of Kansas Medical Center
- The University of Utah
- The V Foundation for Cancer Research
- Tianjin Medical University Cancer Institute and Hospital
- TRACT Therapeutics
- Triumvira Immunologics
- TVAX Biomedical
- TxCell
- UBS Oncology Impact Fund
- UCL Technology Fund
- University College London (UCL)
- University Health Network, Toronto
- University Hospital Cologne
- University Hospital of Saint-Étienne
- University Hospital of Montpellier
- University Hospital of Würzburg
- University Hospital Regensburg
- University of Alabama
- University of Alberta
- University of Arkansas
- University of California
- University of Cambridge
- University of Cincinnati
- University of Colorado
- University of Kansas Medical Center
- University of Kentucky
- University of Liege
- University of Maryland
- University of Miami
- University of Michigan
- University of Minnesota Medical Center
- University of Pennsylvania
- University of Perugia
- University of Pittsburgh
- University of Regensburg
- University of Sydney
- University of Technology Sydney
- University of Texas
- University of Wisconsin
- University of Wisconsin Carbone Cancer Center (UWCCC)
- University of Wisconsin School of Medicine and Public Health
- UW Health
- Vall d'Hebron Institute of Oncology
- V Foundation for Cancer Research
- Versant Ventures
- Vertex Ventures
- Veterans Affairs (VA) Office of Research and Development
- Vida Ventures
- ViGenCell
- Vineti
- Vir Biotechnology
- Viva Biotech
- VT BIO
- Vyriad
- Washington University School of Medicine
- Wellcome Trust
- Westlake Village BioPartners
- WindMIL Therapeutics
- Wuhan Union Hospital
- Xiangxue Life Science Research Center
- Xiangxue Pharmaceutical
- Yale University
- Ysios Capital
- Zhejiang Huahai Pharmaceutical
- Zhujiang Hospital of Southern Medical University
Methodology
LOADING...
